title: Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies.
abstract: Cisplatin and teniposide given by intraperitoneal (IP) route exert a synergistic therapeutic effect against ascitic P388 leukemia in mice. As single agents, they display different dose-limiting toxicities and favourable pharmacokinetic characteristics in IP phase I trials. We administered cisplatin (fixed dose: 200 mg/m2) and teniposide (escalating doses) by IP route without dwell-time to investigate the toxicity, pharmacokinetics and clinical activity of this 2-drug combination. Nine patients received a total of 14 courses. Myelosuppression, nausea and vomiting were the most frequent toxicities. Leukopenia was the dose-limiting toxicity. The maximum tolerated dose of teniposide was 100 mg/m2 when administered with a fixed dose of 200 mg/m2 cisplatin. Pharmacokinetic analysis showed that the main parameters of both cisplatin and teniposide in the peritoneum and in the plasma were not modified when the drugs were combined. It appears that a pharmacodynamic interaction exists between cisplatin and teniposide which results in increased hematologic toxicity. Although an objective response has been observed in one patient with refractory ovarian cancer, such association should not be applicable for further clinical development due to marked toxicity and the low dose of teniposide recommended.
authors.affiliation: Unité de Pharmacologie et de Pharmacocinétique Cliniques, Centre Claudius Regaud, Toulouse France.
authors.forename: E
authors.initials: E
authors.lastname: Chatelut
authors.forename: M
authors.initials: M
authors.lastname: de Forni
authors.forename: P
authors.initials: P
authors.lastname: Canal
authors.forename: C
authors.initials: C
authors.lastname: Chevreau
authors.forename: H
authors.initials: H
authors.lastname: Roche
authors.forename: Y
authors.initials: Y
authors.lastname: Plusquellec
authors.forename: N P
authors.initials: NP
authors.lastname: Johnson
authors.forename: G
authors.initials: G
authors.lastname: Houin
authors.forename: R
authors.initials: R
authors.lastname: Bugat
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D004341:Drug Evaluation; D004357:Drug Synergism; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007941:Leukemia P388 / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D051379:Mice; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000008:administration & dosage; D012074:Remission Induction; D013713:Teniposide / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D005047:Etoposide; D013713:Teniposide; D011034:Podophyllotoxin; D002945:Cisplatin